Stock Analysis

Announcing: L&C Bio (KOSDAQ:290650) Stock Increased An Energizing 163% In The Last Year

  •  Updated
Source: Shutterstock

While L&C Bio Co., Ltd (KOSDAQ:290650) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 13% in the last quarter. On the other hand, over the last twelve months the stock has delivered rather impressive returns. We're very pleased to report the share price shot up 163% in that time. So some might not be surprised to see the price retrace some. Investors should be wondering whether the business itself has the fundamental value required to continue to drive gains.

Check out our latest analysis for L&C Bio

To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

During the last year L&C Bio grew its earnings per share (EPS) by 7.5%. This EPS growth is significantly lower than the 163% increase in the share price. This indicates that the market is now more optimistic about the stock. This favorable sentiment is reflected in its (fairly optimistic) P/E ratio of 108.83.

You can see below how EPS has changed over time (discover the exact values by clicking on the image).

KOSDAQ:A290650 Earnings Per Share Growth February 3rd 2021

It might be well worthwhile taking a look at our free report on L&C Bio's earnings, revenue and cash flow.

A Different Perspective

L&C Bio boasts a total shareholder return of 164% for the last year (that includes the dividends) . We regret to report that the share price is down 13% over ninety days. Shorter term share price moves often don't signify much about the business itself. You might want to assess this data-rich visualization of its earnings, revenue and cash flow.

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on KR exchanges.

If you decide to trade L&C Bio, use the lowest-cost* platform that is rated #1 Overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account. Promoted

Valuation is complex, but we're helping make it simple.

Find out whether L&C Bio is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

About KOSDAQ:A290650

L&C Bio

L&C BIO Co., Ltd. operates as a research and development company in tissue regeneration medicine.

Imperfect balance sheet with poor track record.

Stock Analysis

No articles found